Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown impressive results in clinical trials with weight loss exceeding 24% in some studies
Key Takeaway: Consistency is the goal, but flexibility is the reality
Comparative Analysis Mechanism Comparison Factor Mazdutide Tirzepatide Retatrutide Agonist Type Dual Dual Triple Second Receptor Glucagon GIP Both Developer Innovent/Lilly Eli Lilly Eli Lilly FDA Approved No Yes No (under review) Primary Trial Region China Global Global Research Application Selection When to consider Mazdutide: Research specifically examining glucagon pathway contributions without GIP confounding Studies comparing GLP-1/glucagon vs
Looking for a quick way to boost energy and performance before an event or demanding physical activity
What's the best water to use for reconstituting BPC-157
Thain A, Hart K, Ahmadi KR European journal of clinical nutrition 2025